We walk the talk 

In a 2015 study (1) 44% of the HIV infected adolescents receiving a boosted protease inhibitor treatment had their viral load uncontrolled.  When the adherence was measured using pill count the average adherence was 100% (range = 93–100%). Without the MEMS reliable and rich adherence measurement, the problem would have been seen as a lack of efficacy requiring therapeutic escalation. In fact, the adherence measured with MEMS showed the real issue, an average adherence level of 41% (range = 3–100%).

By moving the focus to adherence management, the real issues can be addressed. Measure, understand and manage…

  • Measure the real adherence in your population
  • Understand which patients are having which problems
  • Manage the barriers, even the ones that the patients were not aware of, set up goals and review the evaluation on the next visit.

MEMS, we provide the tools

You make the difference

Reach out to us at This email address is being protected from spambots. You need JavaScript enabled to view it. to receive more information about the use of the MEMS® (Medication Event Monitoring System).

Best Regards,

The MEMS team

(1) http://sti.bmj.com/content/91/Suppl_2/A33.3